Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
There are chronic hepatitis B patients with poor antiviral efficacy of entecavir in clinical
practice. Tenofovir or interferon alfa is the optimal choice right now. The aim of this study
is to investigate the therapeutic effect of using tenofovir of interferon alfa in these
patients.